We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
Sandbox GGC4
From Proteopedia
(Difference between revisions)
| Line 13: | Line 13: | ||
== Disease == | == Disease == | ||
| - | Mutations in the ''PAX6'' gene are implicated in several diseases in humans, including congenital aniridia both as a standalone disease and also as a part of WAGR syndrome ('''W'''ilms tumor, '''A'''niridia, '''G'''enitourinary anomalies, and mental '''R'''etardation syndrome<ref>PMID:28321846</ref>. Inheritance of mutations in the ''PAX6'' gene happens in an autosomal dominant fashion<refname="recdev" />, resulting in haploinsufficiency where one copy of the chromosome bearing the ''PAX6'' carries a version bearing a loss-of-function mutation<ref>PMID:24138039</ref>. | + | Mutations in the ''PAX6'' gene are implicated in several diseases in humans, including congenital aniridia both as a standalone disease and also as a part of WAGR syndrome ('''W'''ilms tumor, '''A'''niridia, '''G'''enitourinary anomalies, and mental '''R'''etardation syndrome<ref>PMID:28321846</ref>. Inheritance of mutations in the ''PAX6'' gene happens in an autosomal dominant fashion<refname="recdev" />, resulting in haploinsufficiency where one copy of the chromosome bearing the ''PAX6'' carries a version bearing a loss-of-function mutation<ref name="clinical">PMID:24138039</ref>. |
| + | |||
| + | While all of the previously mentioned diseases are a result of this ''PAX6'' haploinsufficiency, ''PAX6'' aniridia syndrome, more commonly known to the general public as aniridia, is the primary manifestation<ref>PMID:28598868</ref>. While the hallmark of aniridia is the patient either lacking an iris or possessing a rudimentary stump of an iris, the disease bears a high incidence of panocular manifestations such as foveal hypoplasia and the underdevelopment of the optic nerve, which can lead to photophobia and poor vision from an early age<ref name="clinical" />. Aniridia patients are also prone to high incidences of glaucoma, corneal keratopathy (fibrosis of the cornea, often as a result of limbal stem cell deficiency, and premature development of cataracts<ref name="recdev" />, all of which lead to patients with aniridia needing a lifetime of specialized care from an ophthalmologist. | ||
| - | While the hallmark of aniridia is the patient either lacking an iris or possessing a rudimentary stump of an iris, the disease bears a high incidence of panocular manifestations such as foveal hypoplasia, the underdevelopment of the optic nerve, and a high incidence of aniridia mutations that lead to the patient possessing only one functional copy of the ''PAX6'' gene (particularly premature termination codons, frame shift mutations, or whole gene deletions | ||
== Relevance == | == Relevance == | ||
| - | + | The significant prevalence of fibrotic diseases such as corneal keratopathy and the premature formation of cataracts as a result of deficiencies in PAX6 and its highly conserved nature allows for research into the molecular mechanisms behind the formation of fibrotic tissue. Any understanding behind the mechanisms of the expression of ''PAX6'' and the link between PAX6 expression and said disorders may be capable of leading to findings that may translate to applications to ameliorate the effects of cataracts and secondary cataracts (posterior capsular opacification) in the general population. | |
| - | + | == Structural highlights == | |
| + | The C-terminal domain of | ||
The <scene name='75/752268/Linker_bound_minor_groove/2'>extended linker region</scene> between the N-terminal and C-terminal domains of PAX6 consists of 15 residues and binds with the sugar phosphate backbone in the minor groove of the DNA being transcribed<ref name="structure" />. | The <scene name='75/752268/Linker_bound_minor_groove/2'>extended linker region</scene> between the N-terminal and C-terminal domains of PAX6 consists of 15 residues and binds with the sugar phosphate backbone in the minor groove of the DNA being transcribed<ref name="structure" />. | ||
Revision as of 13:33, 20 November 2019
Pax6 paired domain protein
| |||||||||||
References
- ↑ Wang X, Shan X, Gregory-Evans CY. A mouse model of aniridia reveals the in vivo downstream targets of Pax6 driving iris and ciliary body development in the eye. Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):60-67. doi:, 10.1016/j.bbadis.2016.10.018. Epub 2016 Oct 20. PMID:27771509 doi:http://dx.doi.org/10.1016/j.bbadis.2016.10.018
- ↑ Stuart ET, Kioussi C, Gruss P. Mammalian Pax genes. Annu Rev Genet. 1994;28:219-36. doi: 10.1146/annurev.ge.28.120194.001251. PMID:7893124 doi:http://dx.doi.org/10.1146/annurev.ge.28.120194.001251
- ↑ 3.0 3.1 Xu HE, Rould MA, Xu W, Epstein JA, Maas RL, Pabo CO. Crystal structure of the human Pax6 paired domain-DNA complex reveals specific roles for the linker region and carboxy-terminal subdomain in DNA binding. Genes Dev. 1999 May 15;13(10):1263-75. PMID:10346815
- ↑ 4.0 4.1 4.2 4.3 Parekh, M., Poli, B., Ferrari, S., Teofili, C., & Ponzin, D. (Eds.). (2015). Aniridia : Recent developments in scientific and clinical research DOI: 10.1007/978-3-319-19779-1
- ↑ Duncan MK, Haynes JI 2nd, Cvekl A, Piatigorsky J. Dual roles for Pax-6: a transcriptional repressor of lens fiber cell-specific beta-crystallin genes. Mol Cell Biol. 1998 Sep;18(9):5579-86. doi: 10.1128/mcb.18.9.5579. PMID:9710641 doi:http://dx.doi.org/10.1128/mcb.18.9.5579
- ↑ Vasilyeva TA, Voskresenskaya AA, Kasmann-Kellner B, Khlebnikova OV, Pozdeyeva NA, Bayazutdinova GM, Kutsev SI, Ginter EK, Semina EV, Marakhonov AV, Zinchenko RA. Molecular analysis of patients with aniridia in Russian Federation broadens the spectrum of PAX6 mutations. Clin Genet. 2017 Dec;92(6):639-644. doi: 10.1111/cge.13019. Epub 2017 Aug 2. PMID:28321846 doi:http://dx.doi.org/10.1111/cge.13019
- ↑ 7.0 7.1 Lee HJ, Colby KA. A review of the clinical and genetic aspects of aniridia. Semin Ophthalmol. 2013 Sep-Nov;28(5-6):306-12. doi: 10.3109/08820538.2013.825293. PMID:24138039 doi:http://dx.doi.org/10.3109/08820538.2013.825293
- ↑ Lim HT, Kim DH, Kim H. PAX6 aniridia syndrome: clinics, genetics, and therapeutics. Curr Opin Ophthalmol. 2017 Sep;28(5):436-447. doi: 10.1097/ICU.0000000000000405. PMID:28598868 doi:http://dx.doi.org/10.1097/ICU.0000000000000405
